Results 201 to 210 of about 716,322 (331)

Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.
Roxane Dilcher   +10 more
wiley   +1 more source

Functional and Structural Evidence of Neurofluid Circuit Aberrations in Huntington Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Disrupted neurofluid regulation may contribute to neurodegeneration in Huntington disease (HD). Because neurofluid pathways influence waste clearance, inflammation, and the distribution of central nervous system (CNS)–delivered therapeutics, understanding their dysfunction is increasingly important as targeted treatments emerge.
Kilian Hett   +8 more
wiley   +1 more source

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

Clinical Validation of Plasma p‐217tau in Neurological Diseases

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi   +13 more
wiley   +1 more source

A 3D comparison of planned versus achieved anterior tooth position in clear aligner treatment. [PDF]

open access: yesSci Rep
Saif BS   +9 more
europepmc   +1 more source

RETRACTION: Downregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion

open access: yesFEBS Open Bio, EarlyView.
RETRACTION: J. Chen, C. Chen, Y. Lin, Y. Su, X. Yu, Y. Jiang, Z. Chen, SY. Ke, SZ. Lin, L. Chen, Z. Zhang, and T. Zhang, “Downregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion,” FEBS Open Bio 11, no. 6 (2021): 1771–1784. https://doi.org/10.1002/2211-5463.13173. The above article, published online on 14 May
wiley   +1 more source

Home - About - Disclaimer - Privacy